0001209191-14-008352.txt : 20140207 0001209191-14-008352.hdr.sgml : 20140207 20140207160400 ACCESSION NUMBER: 0001209191-14-008352 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140205 FILED AS OF DATE: 20140207 DATE AS OF CHANGE: 20140207 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Connolly Thomas CENTRAL INDEX KEY: 0001453943 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 14584355 MAIL ADDRESS: STREET 1: 717 FIFTH AVENUE STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2014-02-05 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001453943 Connolly Thomas C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 SVP, Human Resources Common Stock 2014-02-05 4 A 0 11875 0.01 A 15647 D Common Stock 2014-02-05 4 M 0 938 45.11 A 16585 D Common Stock 2014-02-05 4 S 0 200 76.82 D 16385 D Common Stock 2014-02-05 4 S 0 738 77.83 D 15647 D Common Stock 150 I 401(k) Employee Stock Option (right to buy) 77.31 2014-02-05 4 A 0 62750 0.00 A 2024-02-04 Common Stock 62750 62750 D Employee Stock Option (right to buy) 45.11 2014-02-05 4 M 0 938 0.00 D 2023-02-04 Common Stock 938 11250 D Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products. Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $76.82 (range $76.49 to $77.14). Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $77.83 (range $77.47 to $78.13). The option vests in 16 quarterly installments from 02/05/2014. The option vests in 16 quarterly installments from 02/05/2013. Kenneth L. Horton, Attorney-In-Fact 2014-02-07